Eris Lifesciences Limited IPO: Issue Price, Listing Gain and Share Price Now
Eris Lifesciences Limited listed on 29-Jun-2017 at ₹601.05 against an issue price of ₹603 , a listing change of -0.32%. It last traded at ₹1,325.4. This page is the record of that issue and what has happened to it since — reported figures only.
Eris Lifesciences Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹603 |
| Listing price (listing-day close) | ₹601.05 |
| Listing gain | -0.32% |
| Price now | ₹1,325.4 |
| Change from issue price | +119.80% |
| Change from listing-day close | +120.51% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Eris Lifesciences Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹603 |
| Issue size | ₹1,740.49 Cr |
| Offer for sale | ₹1,740.49 Cr |
| Issue opened | 16-Jun-2017 |
| Issue closed | 20-Jun-2017 |
| Listed on | 29-Jun-2017 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | Axis Capital (left lead) |
How the Eris Lifesciences Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 4.68x |
| NII | 0.45x |
| Retail | 3.51x |
| Total | 3.29x |
Eris Lifesciences Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹18,376 Cr |
| Trailing P/E | 28.00x |
| Return on capital employed | 14.1% |
| Return on equity | 18.7% |
| 52-week high | ₹1,819 |
| 52-week low | ₹1,200 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Eris Lifesciences Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.